This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated
with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in
the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more
about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand
how well patients respond to treatment.
I. To determine whether leukemia and lymphoma patients from P9404, P9425, P9426, and Dana
Farber Cancer Institute (DFCI) 95-01 randomized to the experimental dexrazoxane hydrochloride
(DRZ) arms have decreased markers of cardiomyopathy/heart failure (CHF) compared with
patients on the standard arm.
II. To determine whether osteosarcoma patients from P9754 (all received DRZ) have decreased
markers of cardiomyopathy/heart failure (CHF) compared with similarly treated osteosarcoma
patients diagnosed during the same time period, but who did not receive DRZ.
III. To evaluate whether the cardioprotective effect of DRZ is modified by anthracycline
(anthracycline analogue GPX-150) dose, chest radiation, and demographic factors (age at
cancer diagnosis, current age, sex).
I. To determine whether leukemia and lymphoma patients from P9404, P9425, P9426, and DFCI
95-01 on the DRZ arms experienced differential rates of overall-survival and event-free
survival compared with the standard therapy arms.
II. To determine whether projected quality-adjusted life years (QALY) differed by DRZ status,
accounting for premature cardiac disease, primary disease relapse, and second cancers.
III. Determine the longitudinal trajectory of 2-dimensional echocardiographic parameters
(focusing on left ventricular [LV] function and remodeling/geometric changes that can be
reliably re-measured) among patients from time of cancer treatment through subsequent
Patients complete a diagnostic symptom checklist, undergo a physical exam, echocardiogram,
collection of serum for biomarker testing, and a 6 minute walk test, and complete quality of
life, family history, physical activity, and smoking questionnaires.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.